Can you give me some information on Ebola and Marburg virus disease?

Answer 1

I'm not sure what type or what level of information you want, so...

Ebola and Marburg are types of filoviruses. They are also known as hemmoraghic viruses because of the hemoraging they cause in victim's organs. They have genomes made of RNA, not DNA. They have been found mostly in Africa, but the natural reservoir (normal host) is not known. Transmission occurs most frequently through contact with blood and/or bodily fluids, but has not been reported to be transmitted aerially. Incubation period is 2 to 21 days, often resulting in death, but occasionally patients recover.

Answer 2

I dont know about Marburg Virus but Ebola Virus is the dangerous virus.

Answer 3

Ebola virus (EBOV) causes acute severe haemorrhagic fever leading to up to 90% lethality. Increasingly frequent outbreaks and the placement of EBOV in the category A list of potential biothreat agents have boosted interest in this virus.
The disease closely resembles Marburg virus disease. Ebola Virus Disease has a high mortality.
Furthermore, development of new technologies (e.g. reverse genetics systems) and extensive studies on Ebola haemorrhagic fever (EHF) in animal models have substantially expanded the knowledge on the pathogenic mechanisms that underlie this disease.
Two major factors in EBOV pathogenesis are the impairment of the immune response and vascular dysfunction.
Ebola virus infection was first recognized during a human outbreak in 1976 with almost simultaneous outbreaks in both the Sudan and Zaire (now the Democratic Republic of the Congo). It was named after a river in the Democratic Republic of the Congo.
The Ebola virus is now known to have four subtypes : Zaire, Sudan, Reston, and Ivory Coast .
Although the natural host and the route of transmission are uncertain, the ebola virus appears to be spread mainly by close and prolonged contact with an infected person or by inoculation from contaminated syringes and needles.
http://www.histopathology-india.net/ebola_virus.htm

Marburg virus disease, a severe, distinctive, hemorrhagic illness with a high rate of mortality, is heralded early by severe sore throat, a maculopapular rash, and a red exanthem on the hard and soft palate.
Later, severe, generalized bleeding dominates the clinical course.
The disease was first recognized in 1967 in Marburg, Germany, and in Yugoslavia among laboratory workers exposed to blood and tissues from African green monkeys imported from Uganda. There have been subsequent outbreaks in South Africa, Kenya, and Zimbabwe.
The Marburg and Ebola viruses are interpreted as the first recognized viruses of the family, the Filoviridae.
Marburg hemorrhagic fever has affected many fewer persons than Ebola virus. Thus, the recent large outbreak that was declared over in November 2005 is of particular interest, especially since before this outbreak, cases in children were rare, and in this outbreak, children account for a high proportion of those affected.
Transmission of these viruses occurs by direct contact with infected body fluids from animals and humans, such as blood, saliva, vomitus, respiratory droplets, urine and stool, and contact with virus-contaminated objects (e.g. needles, syringes).
Persons who prepare, cook, and eat contaminated animals may become infected.
Person-to-person transmission occurs, as does infection from direct inoculation. Transmission via semen may occur weeks after recovery.
It is extremely important to use proper barrier nursing techniques to prevent secondary cases of Ebola and Marburg virus hemorrhagic fevers to caretakers and families, including use of standard, contact, and airborne isolation precautions. http://www.histopathology-india.net/marburg_virus.htm

Answer 4

The media will reason human beings LIKE ME to do something awful. it really is their job. The Pharmaceutical complainers will make billions making a vaccine it really is what they favor. This virus changed into contained contained in the 70's Why not now This us of a is complete of greed they deliver youthful adult males to die for them in made up wars like IRAQ. i will do something undesirable . i favor help and the media is causes me rigidity and that i do not have the and to get help for it. i desire wel all DIE> I HATE us of a I HATE us of a I CURSE us of a

Answer 5

yes...don't catcht them, absolutely fatal....both diseases of monkeys,

Answer 6

Ebola is the common term for a group of viruses belonging to genus Ebolavirus, family Filoviridae, which cause Ebola hemorrhagic fever.[1] The disease can be deadly and encompasses a range of symptoms including vomiting, diarrhea, changes in skin color, general body pain, internal and external bleeding, and fever.[2] Mortality rates are generally high, ranging from 50% - 90%,[3] with the cause of death usually due to hypovolemic shock or Multiple organ dysfunction syndrome.[4]

The virus is named after the Ebola River in the African nation-state of the Democratic Republic of the Congo (formerly Zaïre), near the site of the first outbreaks.[5] The Democratic Republic of Congo has been the site of four recent outbreaks, including one in May 2005.

Ebola is believed to be a zoonotic virus, although despite considerable effort by the World Health Organization, no animal reservoir capable of sustaining the virus between outbreaks has been identified. One possible candidate reservoir is the fruit bat.[6] Another is the dog. [7]

Because Ebola is lethal and since no approved vaccine or treatment is available, Ebola is classified as a Biosafety Level 4 agent, as well as a Category A Bioterrorism agent[8] and a select agent by the CDC.

The symptoms of Ebola are rather similar to that of the Marburg virus, which is also in the family Filoviridae.

STRUCTURE
Electron micrograph of the filamentous structure of Ebola
[edit] Size and shape
Electron micrographs of members of Ebolavirus show them to have the characteristic thread-like structure of a filovirus. The virions are variable in shape and may appear as a "U", "6", coiled, circular, or branched shape, however, laboratory purification techniques, such as centrifugation, may contribute to the various shapes seen. Virions are generally 80 nm in diameter. They are variable in length, and can be up to 1400 nm long. On average however, the length of a typical Ebola virus is closer to 1000 nm. In the center of the virion is a structure called nucleocapsid, which is formed by the helically wound viral genomic RNA complexed with the proteins NP, VP35, VP30 and L. It has a diameter of 40 – 50 nm and contains a central channel of 20 – 30 nm in diameter. Virally encoded glycoprotein (GP) spikes 10 nm long and 10 nm apart are present on the outer viral envelope of the virion, which is derived from the host cell membrane. Between envelope and nucleocapsid, in the so called matrix space, the viral proteins VP40 and VP24 are located.


GENOME
Each virion contains one molecule of linear, single-stranded, negative-sense RNA, totalling 18900 nucleotides in length. The 3′ terminus is not polyadenylated and the 5′ end is not capped. It codes for seven structural proteins and one non-structural protein. The gene order is 3′ - leader - NP - VP35 - VP40 - GP/sGP - VP30 - VP24 - L - trailer - 5′; with the leader and trailer being non-transcribed regions which carry important signals to control transcription, replication and packaging of the viral genome into new virions. The genomic material by itself is not infectious, because viral proteins, among them the RNA-dependent RNA polymerase, are necessary to transcribe the viral genome into mRNAs, as well as for replication of the viral genome.


SPECIES

- Zaïre Ebolavirus
The Zaïre Ebolavirus has the highest mortality rate, up to 90% in some epidemics, with an average of approximately 83% mortality over 27 years. The case-fatality rates were 88% in 1976, 100% in 1977, 59% in 1994, 81% in 1995, 73% in 1996, 80% in 2001-2002 and 90% in 2003. There have been more outbreaks of Zaïre Ebolavirus than any other strain.

The first outbreak took place on August 26, 1976 in Yambuku, a town in the north of Zaïre. The first recorded case was Mabalo Lokela, a 44-year-old schoolteacher returning from a trip around the north of the state. His high fever was diagnosed as possible malaria and he was subsequently given a quinine shot. Lokela returned to the hospital every day. A week later, his symptoms included uncontrolled vomiting, bloody diarrhea, headache, dizziness, and trouble breathing. Later, he began bleeding from his nose, mouth, and rectum. Mabalo Lokela died on September 8, 1976, roughly 14 days after the onset of symptoms.


A graphical representation of known human cases and deaths during outbreaks of Zaïre Ebolavirus between 1976 and 2003Soon after, more patients arrived with varying but similar symptoms including fever, headache, muscle and joint aches, fatigue, nausea and dizziness. These often progressed to bloody diarrhea, severe vomiting, and bleeding from the nose, mouth, and rectum. The initial transmission was believed to be due to reuse of the needle for Lokela’s injection without sterilization. Subsequent transmission was also due to care of the sick patients without barrier nursing and the traditional burial preparation method, which involved washing and gastrointestinal tract cleansing.


- Sudan Ebolavirus
Sudan Ebolavirus was the second strand of Ebola reported in 1976. It apparently originated amongst cotton factory workers in Nzara, Sudan. The first case reported was a worker exposed to a potential natural reservoir at the cotton factory. Scientists tested all animals and insects in response to this, however none tested positive for the virus. The carrier is still unknown.

A second case involved a nightclub owner in Nzara, Sudan. The local hospital, Maridi, tested and attempted to treat the patient; however, nothing was successful, and he died. The nurses did not apply safe and practical procedures in sterilizing and disinfecting the medical tools used on the nightclub owner, facilitating the spread of the virus in the hospital.

The most recent outbreak of Sudan Ebolavirus occurred in May 2004. As of May 2004, 20 cases of Sudan Ebolavirus were reported in Yambio County, Sudan, with 5 deaths resulting. The Centers for Disease Control and Prevention confirmed the virus a few days later. The neighbouring countries of Uganda and the Democratic Republic of Congo have increased surveillance in bordering areas, and other similar measures have been taken to control the outbreak. The average fatality rates for Sudan Ebolavirus were 53% in 1976, 68% in 1979, and 53% in 2000/2001. The average case-fatality rate is 53.76%.


A graphical representation of known human cases and deaths during outbreaks of Sudan Ebolavirus between 1976 and 2003

- Reston Ebolavirus
Main article: Ebola Reston
First discovered in November of 1989 in a group of 100 Crab-eating monkeys (Macaca fascicularis) imported from the Philippines to Reston, Virginia. A parallel infected shipment was also sent to Philadelphia. This strain was highly lethal in monkeys, but did not cause any fatalities in humans. Six of the Reston primate handlers tested positive for the virus, two due to previous exposure.

Further Reston Ebolavirus infected monkeys were shipped again to Reston, and Alice, Texas in February of 1990. More Reston Ebolavirus infected monkeys were discovered in 1992 in Siena, Italy and in Texas again in March 1996. A high rate of co-infection with Simian Hemorrhagic Fever (SHF) was present in all infected monkeys. No human illness has resulted from these two outbreaks.


- Ivory Coast Ebolavirus
This species of Ebola was first discovered amongst chimpanzees of the Tai Forest in Côte d’Ivoire, Africa. On November 1, 1994, the corpses of two chimpanzees were found in the forest. Necropsies showed blood within the heart to be liquid and brown, no obvious marks seen on the organs, and one presented lungs filled with liquid blood. Studies of tissues taken from the chimps showed results similar to human cases during the 1976 Ebola outbreaks in Zaïre and Sudan. Later in 1994, more dead chimpanzees were discovered, with many testing positive to Ebola using molecular techniques. The source of contamination was believed to be the meat of infected Western Red Colobus monkeys, which the chimpanzees preyed upon.[9]

One of the scientists performing the necropsies on the infected chimpanzees contracted Ebola. She developed syndromes similar to dengue fever approximately a week after the necropsy and was transported to Switzerland for treatment. After two weeks she was discharged from hospital, and was fully recovered six weeks after the infection.


- Replication
The viral attachment protein recognizes specific receptors, which may be protein, carbohydrate or lipid, on the outside of the cell. The mechanism of virus entry into host cells is unknown, but it is reasonable to assume that the glycoprotein spikes on the surface of the virion would mediate the process, as they are the only transmembrane protein present on the surface. The two types of GP, the other being sGP, are specific for different cell types.

The virus next activates and releases its own genetic material, causing the host to begin manufacturing the proteins necessary for virus reproduction using its own resources. This replication continues until the cell ruptures and bursts. The virus is then spread to neighboring cells, and continues this chain of reproduction until masses of host cells are damaged. The host then may die soon after. The spread of the virus through the population can be halted if the proper sterilization and quarantine measures are taken, as the only method by which the virus may continue to propagate is via direct contact with body fluids. In order for a successful infection the virus must first evade the immune system. One of the ways it does this is by inhibiting interferon activity. VP24 blocks IFN-α/β and IFN-γ signaling by interacting with karyopherin α1, the nuclear localization signal receptor for tyrosine-phosphorylated STAT1, preventing the formation of an interferon induced antiviral state. Another protein, VP35, blocks the transcription factor interferon regulatory factor 3 (IRF-3), which is important for the expression of IFN-α/β.

- Ebola hemorrhagic fever

- Symptoms

1976 photograph of two nurses standing in front of Kinshasa case #3 (Nurse Mayinga) who was treated and later died in Ngaliema Hospital, in Kinshasa, ZaïreSymptoms are varied and often appear suddenly. Initial symptoms include: high fever (at least 38.8°C/101°F), severe headache, muscle, joint, or abdominal pain, severe weakness and exhaustion, sore throat, nausea, and dizziness. Before an outbreak is suspected, these early symptoms are easily mistaken for malaria, typhoid fever, dysentery, influenza, or various bacterial infections, which are all far more common.

Ebola goes on to cause diarrhea, dark or bloody stool, vomiting blood, red eyes from swollen blood vessels, red spots on the skin from subcutaneous bleeding, maculopapular rash, purpura, and bleeding internally and externally from any orifice, including from the nose, mouth, rectum, genitals or needle puncture sites.

Other secondary symptoms include hypotension (less than 90mm Hg), hypovolemia, tachycardia, severe organ damage (especially the kidneys, spleen, and liver) as a result of disseminated systemic necrosis, and proteinuria. The span of time from onset of symptoms to death (usually due to hypovolemic shock and/or multiple organ failure) is usually between 7 and 14 days. By the second week of infection, patients will either defervesce (the fever will lessen) or undergo systemic multiorgan failure.


- Transmission
Among humans, the virus is transmitted by direct contact with infected body fluids, or to a lesser extent, skin or mucus membrane contact. The incubation period can be anywhere from 2 to 21 days, but is generally between 5 and 10 days.

Although airborne transmission between monkeys has been demonstrated in a laboratory, there is very limited evidence for human-to-human airborne transmission in any reported epidemics. Nurse Mayinga might represent the only possible case. The means by which she contracted the virus remain uncertain.

So far all epidemics of Ebola have occurred in sub-optimal hospital conditions, where practices of basic hygiene and sanitation are often either luxuries or unknown to caretakers and where disposable needles and autoclaves are unavailable or too expensive. In modern hospitals with disposable needles and knowledge of basic hygiene and barrier nursing techniques, Ebola rarely spreads on such a large scale.

In the early stages, Ebola may not be highly contagious. Contact with someone in early stages may not even transmit the disease. As the illness progresses, bodily fluids from diarrhea, vomiting, and bleeding represent an extreme biohazard. Due to lack of proper equipment and hygienic practices, large scale epidemics occur mostly in poor, isolated areas without modern hospitals and/or well-educated medical staff. Many areas where the infectious reservoir exists have just these characteristics. In such environments all that can be done is to immediately cease all needle sharing or use without adequate sterilization procedures, to isolate patients, and to observe strict barrier nursing procedures with the use of a medical rated disposable face mask, gloves, goggles, and a gown at all times. This should be strictly enforced for all medical personnel and visitors.


- Treatments
Treatment is primarily supportive and includes minimizing invasive procedures, balancing electrolytes, replacing lost coagulation factors to help stop bleeding, maintaining oxygen and blood levels, and treating any complicating infections. Despite some initial anecdotal evidence, blood serum from Ebola survivors has been shown to be ineffective in treating the virus. Interferon is also thought to be ineffective. In monkeys, administration of an inhibitor of coagulation (rNAPc2) has shown some benefit, protecting 33% of infected animals from a usually 100% (for monkeys) lethal infection. In early 2006, scientists at USAMRIID announced a 75% recovery rate after infecting four rhesus monkeys with Ebola virus and administering antisense drugs.[10]


- Vaccines
Vaccines have been produced for both Ebola and Marburg that were 100% effective in protecting a group of monkeys from the disease.[11] These vaccines are based on either a recombinant Vesicular stomatitis virus or a recombinant Adenovirus[12] carrying the Ebola spikeprotein on its surface. Early human vaccine efforts, like the one at NIAID in 2003, have so far not reported any successes.[13]